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Abstract
Glaucoma is a leading cause of acquired blindness which may involve an ischemic-like insult to retinal ganglion cells and
optic nerve head. We investigated the effect of a weekly application of brief ischemia pulses (ischemic conditioning) on the
rat retinal damage induced by experimental glaucoma. Glaucoma was induced by weekly injections of chondroitin sulfate
(CS) in the rat eye anterior chamber. Retinal ischemia was induced by increasing intraocular pressure to 120 mmHg for
5 min; this maneuver started after 6 weekly injections of vehicle or CS and was weekly repeated in one eye, while the
contralateral eye was submitted to a sham procedure. Glaucoma was evaluated in terms of: i) intraocular pressure (IOP), ii)
retinal function (electroretinogram (ERG)), iii) visual pathway function (visual evoked potentials, (VEPs)) iv) histology of the
retina and optic nerve head. Retinal thiobarbituric acid substances levels were assessed as an index of lipid peroxidation.
Ischemic conditioning significantly preserved ERG, VEPs, as well as retinal and optic nerve head structure from
glaucomatous damage, without changes in IOP. Moreover, ischemia pulses abrogated the increase in lipid peroxidation
induced by experimental glaucoma. These results indicate that induction of ischemic tolerance could constitute a fertile
avenue for the development of new therapeutic strategies in glaucoma treatment.
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Introduction
Glaucoma is a leading cause of blindness worldwide, charac-
terized by specific visual field defects due to the loss of retinal
ganglion cells (RGCs) and damage to the optic nerve head (ONH).
The result is a patchy loss of vision, generally in a peripheral to
central manner. It is estimated that half of those affected may not
be aware of their condition because symptoms may not occur
during the early stages of the disease. When vision loss appears,
considerable permanent damage has already occurred. Medica-
tions and surgery can help to slow the progression of some forms of
the disease, but there is no cure at present.
Unraveling which are the most critical mechanisms involved in
glaucoma is unlikely to be achieved in studies which are limited to
the clinically observable changes to the retina and optic nerve
head that are seen in human glaucoma. Far more detailed and
invasive studies are required, preferably in a readily available
animal model. Recently, we have developed a model of glaucoma
in rats through weekly injections of chondrotin sulfate (CS) in the
eye anterior chamber. Acute or chronic intracameral injections of
CS significantly increase IOP as compared with vehicle-injected
eyes [1]. Moreover, injections of CS for 6 or 10 (but not 3) weeks
significantly decrease the electroretinographic activity as well as
flash visual evoked potentials (VEPs). After 10 weeks of ocular
hypertension induced by CS, a significant loss of ganglion cell
layer (GCL) cells and optic nerve fibers occurs in eyes treated with
CS [1]. These results indicate that weekly intracameral injections
of CS mimic central features of human primary open-angle
glaucoma. Thus, this model could be a useful tool for
understanding the pathogenic mechanisms involved in glaucoma-
tous neuropathy, as well as for the development of new therapeutic
strategies.
The major risk factor for glaucoma is the increased intraocular
pressure (IOP), and its pharmacological and/or surgical reduction
slows down the progression of glaucomatous damage. However,
lowering ocular hypertension does not completely stop damage
progression, indicating risk factors other than IOP. It has been
consistently suggested that an elevation of IOP evokes a variety of
consequential events, including reduction in blood flow which
leads to a partial ischemic insult [2,3]. In that sense, several
evidences support a localized vascular insufficiency leading to
perfusion deficits of ocular structures, including the ONH, the
retina, the choroid, and the retrobulbar vessels [4]. Combined
with high IOP, ischemic mechanisms can cause oxidative stress,
reperfusion damage, and ultimately axon loss [5]. Several animal
and human studies have indicated that vascular dysregulation and
ischemia play a role in glaucoma pathogenesis [6–9]. Retinal
ischemia develops when retinal blood flow is insufficient to match
the metabolic needs of the retina, one of the highest oxygen-
consuming tissues. Ischemia impairs retinal energy metabolism,
and triggers a reaction cascade which can result in cell death.
Oxidative stress, excitotoxicity, calcium influx, and others mechanisms
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damage (reviewed in [10]). Notably, most of these mechanisms are
also involved in glaucomatous neuropathy [11,12]. Although there
is no effective treatment against retinal ischemic injury, it is possible
to activate an endogenous protection mechanism by ischemic
preconditioning (IPC) [13,14]. IPC requires a brief period of
ischemia applied before ischemic injury, which does not produce
any significant damage per se, and induces tolerance to the
subsequent severely damaging ischemic event (reviewed in [15]).
In fact, it has been shown that IPC affords the retina a robust
functional protection against ischemic damage [13]. Although IPC
confersa highly significant neuroprotection in differentin vitro and in
vivo models of ischemia, its utilization as a clinical strategy is mostly
limited because the onset of retinal ischemia is largely unpredict-
able, in contrast to the onset of reperfusion that could be more
predictable. In this vein, another endogenous form of ischemic
protection, in which a short series of repetitive cycles of brief
ischemia/reperfusion (I/R) are applied immediately at the onset of
reperfusion, termed postconditioning (PostC), has been reported in
several tissues [16,17]. Recently, we have shown that a 7-min pulse
of ischemia applied 5 min after the reperfusion onset, induces an
almost complete histological and functional protection in eyes
exposed to ischemic injury [18]. Based on the highly effective
protection induced by IPC and PostC against an acute ischemic
episode, the aim of this work was to analyze the effect of brief
ischemia pulses on retinal damage induced by experimental
glaucoma.
Results
Table 1 depicts the average IOP of rats weekly injected with
vehicle or CS submitted to ischemia pulses or sham procedure at
6, 7, 8, 9, and 10 weeks of intracameral injections of vehicle or CS.
IOP was significantly higher in CS- than in vehicle-injected eyes,
whereas ischemia pulses did not modify IOP in both groups at all
the time points examined.
In order to assess the effect of ischemia pulses on functional
alterations induced by ocular hypertension, the functional state of
retinas from eyes weekly injected with vehicle or CS for 10 weeks
without or with ischemia pulses was analyzed by scotopic
electroretinography. The average amplitudes of scotopic ERG a-
and b- waves of rats bilaterally injected with vehicle or CS for 10
weeks and submitted to weekly ischemia pulses in one eye and a
sham procedure in the contralateral eye are depicted in Figure 1.
These parameters were significantly reduced in eyes which received
CS with sham procedure as compared with vehicle-injected eyes.
The application of ischemia pulses significantly abrogated the
ocular hypertension-induced decrease in ERG a- and b-wave
amplitude. Representative scotopic ERG traces from all the groups
are shown in the lower panel of Figure 1. To assess the visual
pathway function, flash VEPs were registered at 10 weeks of ocular
hypertension induced by weekly injections of CS. A significant
decrease in the VEP N2-P2 component amplitude was observed in
eyes injected with CS without ischemia pulses as compared with
vehicle-injected eyes, whereas a significant preservation of the VEP
N2-P2 component was observed in hypertensive eyes submitted to
ischemia pulses (Figure 2). No noteworthy differences in the VEP
N2-P2 component latency were observed among groups (data not
shown). Representative waveforms of VEPs for all groups areshown
in the right panel of Figure 2. ERGs and VEPs in vehicle-injected
eyes submitted to a sham procedure did not differ from those of
vehicle-injected eyes submitted to ischemia pulses.
The effect of ischemia pulses on histological alterations induced
by ocular hypertension was examined. A morphometric analysis of
retinal sections performed at 10 weeks of treatment with vehicle or
CS revealed no differences in the total retina, IPL, INL, OPL and
ONL thickness (data not shown), whereas a significant decrease in
the number of cells in the GCL was observed in CS-treated eyes
submitted to a sham procedure. Ischemia pulses prevented GCL
cell loss, as shown in Figure 3 (upper panel). NeuN-positive cells in
the retina from vehicle or CS-injected eyes without or with
ischemia pulses were counted, and these sections were counter-
stained with the fluorescent nuclear stain DAPI (Figure 3, middle
panel). A statistically significant increase in the number of H&E
stained cells, NeuN positive cells, and DAPI-labeled cells in the
GCL was observed in hypertensive eyes submitted to ischemia
pulses, as compared with hypertensive eyes submitted to a sham
procedure (Figure 3, lower panel). Ocular hypertension induced a
significant decrease in the number of Thy-1 positive cells, whereas
a significant preservation of Thy-1 positive cell number was
observed in hypertensive eyes submitted to ischemia pulses, as
shown in Figure 4. Apoptotic cell death was evaluated by the
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) method. A significant increase in the number of
TUNEL
+ cells in the GCL was observed in the retina from eyes
injected with CS and submitted to a sham procedure, whereas
ischemia pulses significantly decreased the number of apoptotic
cells (Figure 4). No TUNEL
+ cells were observed in retinas from
eyes injected with vehicle and submitted to ischemia pulses or
sham procedure (data not shown).
Axons in the ONH from vehicle-injected eyes were generally
uniform in shape (rounded) and showed a variable size (Figure 5A).
The ONH from eyes treated with CS for 10 weeks without ischemia
pulses exhibited an overall loss of staining uniformity and integrity,
showing distention and distortion that resulted in a departure from
the circular morphology of normal axons (Figure 5B). The applica-
tion of ischemia pulses significantly preserved ONH structure
(Figure 5C). No changes in the transversal area of the optic nerve
were observed among vehicle-injected and CS-injected eyes
submitted to ischemia pulses or sham procedure (i.e. transversal
area of the optic nerve was: 0.21760.01; 0.21360.02; 0.2176 0.02
and 0.21660.01 mm
2, for vehicle + sham, vehicle + pulses, CS +
sham, CS + ischemia pulses, respectively), but a significant decrease
in the axon number was observed in eyes injected with CS, which
was prevented by ischemia pulses (Figure 5D).
Table 1. Effect of ischemia pulses on IOP in vehicle and CS-
injected eyes.
Intraocular pressure (mmHg)
vehicle CS
sham pulses sham pulses
6 weeks 11.3060.5 12.160.8 22.161.1** 21.461.6**
7 weeks 11.860.8 11.860.6 24.661.5** 22.361.5**
8 weeks 12.060.6 11.960.7 23.461.3** 24.661.0**
9 weeks 11.760.8 12.160.9 24.861.6** 23.961.5**
10 weeks 11.960.6 11.560.7 22.061.0** 21.461.5**
TonoPen measurements of IOP from eyes bilaterally injected with vehicle or CS
and submitted to ischemia pulses or sham procedure. IOP was assessed at 6, 7,
8, 9, and 10 weeks of weekly intracameral injections. At all time points
examined, CS significantly increased IOP as compared with vehicle-injected
eyes. Ischemia pulses did not modify this parameter in vehicle or CS-injected
eyes at any time point. Data are the mean 6 SEM (n=10 animals per group).
**p,0.01 versus vehicle-injected eyes without ischemia pulses (sham), by
Tukey’s test.
doi:10.1371/journal.pone.0023763.t001
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protection induced by ischemia pulses, retinal lipid peroxidation
was examined. Chronic injections of CS without ischemia pulses
significantly increased thiobarbituric acid reactive substances
(TBARS) levels, whereas the application of ischemia pulses
significantly decreased this parameter, as shown in Figure 6.
Discussion
The present results indicate that a weekly application of 5-min
retinal ischemia pulses which showed no effect per se, abrogated
functional and histological alterations induced by chronic ocular
hypertension. Notably, the retinal protection induced by ischemia
pulses was independent from ocular hypertension, as shown by the
fact that ischemia pulses did not affect the increase in IOP induced
by CS injections.
Human open angle glaucoma is a progressive optic neuropathy.
In agreement, we have identified different stages in the
experimental model of glaucoma induced by weekly injections of
CS, that show the following characteristics: i) 3 weeks of ocular
hypertension: no changes in the ERG, VEPs, and retinal
morphology (i.e. asymptomatic ocular hypertension); ii) 6
weeks of ocular hypertension: decrease in ERG and VEPs, without
histological changes (i.e. moderated glaucoma); and iii) 10
weeks of ocular hypertension: further decrease in ERG and VEPs
(vs. 6 weeks), and loss of RGCs and optic nerve fibers (i.e.
advanced glaucoma) [1]. In order to assess whether the
induction of ischemic tolerance was able to reduce glaucoma
progression, the application of ischemia pulses started at 6 weeks of
treatment with CS, a time point in which functional alterations are
already evident.
Several observations support that some components of the flash
ERG [19,20] and VEPs [21,22] can be affected in experimental
models of glaucoma. The weekly application of ischemia pulses,
which did not show any effect in control retinas, prevented the
decrease in the ERG a- and b-wave and flash VEP N2-P2
amplitude induced by chronic ocular hypertension, supporting
that the induction of ischemic tolerance not only preserved the
Figure 1. Electroretinographic preservation in hypertensive eyes induced by the application of brief ischemia pulses. ERGs were
registered after 10 weeks of treatment with vehicle or CS. CS induced a significant decrease in ERG a- and b-wave amplitude, as compared with
vehicle-injected eyes. In hypertensive eyes submitted to ischemia pulses, a significant reversion of these alterations was observed. The lower panel
shows representative scotopic ERG traces from eyes injected with vehicle or CS without or with ischemia pulses. Data are the mean 6 SEM (n=10
animals per group); **p,0.01 versus vehicle injected eyes without ischemia pulses (sham); a: p,0.05, versus CS-injected eyes without ischemia pulses
(sham), by Tukey’s test.
doi:10.1371/journal.pone.0023763.g001
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from photoreceptors to visual cortex, including RGCs and their
axons.
In addition to RGCs, the GCL is comprised of a number of
displaced amacrine cells. NeuN is a DNA-binding protein that
identifies most mature neuronal populations, which has been used
as a specific marker for RGCs [23-25], while Thy-1 is a surface
glycoprotein uniquely expressed in RGCs. In the retina from eyes
injected with CS without ischemia pulses, a significant loss of GCL
cells, as shown by H&E and DAPI staining, and NeuN and Thy-1
immunohistochemistry was observed, without changes in IPL,
INL, OPL, and ONL thickness. Ischemia pulses significantly
reduced the effect of ocular hypertension on the number of cells in
the GCL, as well on the number of apoptotic cells in the GCL. In
addition, a significant decrease in the axon number was evident in
hypertensive eyes without ischemia pulses, whereas ischemic
conditioning significantly prevented the effect of ocular hyperten-
sion on ONH axon number.
Although the influence of duration and frequency of ischemia
pulses on retinal protection deserves to be further examined, these
results indicate that a significant restoration of retinal alterations
provoked by chronic ocular hypertension can be achieved by the
procedure performed herein.
Evidence has progressively accumulated to suggest that vascular
insufficiency plays an important role in the pathogenesis of
glaucomatous neuropathy, and a strong case has been made out to
support the view that glaucoma may involve an ischemic-like insult
to RGCs [6,26]. IPC and PostC are highly effective strategies to
protect the retina from an acute and deleterious ischemic episode.
The precise mechanisms responsible for the retinal protection
against glaucomatous damage induced by ischemia pulses remain
to be established. Several common mechanisms have been
involved in glaucomatous and ischemic damage. Oxidative stress,
excitotoxicity, cell acidosis, inflammation, and others mechanisms
acting in tandem are of considerable importance in both retinal
ischemia and glaucoma. Among all retinal neurons, RGCs are
most susceptible to ischemic and glaucomatous damage [27].
Several lines of evidence support that oxidative damage plays a
major role in glaucoma pathogenesis [11,28]. In that sense, we
have demonstrated that ocular hypertension provokes a significant
decrease in the retinal endogenous antioxidant defense system
activity [11]. Moreover, retinal lipid peroxidation significantly
increases in a time-of-hypertension-dependent manner [11]. The
present results indicate that ocular hypertension induced by
chronic injections of CS significantly increased retinal lipid
peroxidation, and that induction of ischemic tolerance decreased
this parameter. Thus, without excluding the activation of other
transduction pathways associated with retinal IPC, such as
adenosine, KATP channels, Protein Kinase C, heat shock proteins
and NO [14,29,30] among others, and based on the fact that
ischemia pulses abrogated the increase in lipid peroxidation, it is
tempting to speculate that the induction of ischemic conditioning
could behave as an antioxidant therapy.
Brief ischemia or hypoxia serve as prototypical conditioning
stimuli; however, ischemic tolerance can be induced by exposing
animals or cells to diverse type of endogenous or exogenous stimuli
that are not necessarily hypoxic or ischemic in nature, such as
hyperbaric oxygenation [31], or hyperthermia [32] among others.
Recently, we have shown that a moderate inflammation induced by
a single intravitreal injection of bacterial lipopolysaccharide
provides retinal protection against ischemia/reperfusion injury
[33]. In fact, IPC also induces retinal protection against a non-
ischemic insult, such as light-induced injury [34]. It has been
postulated that ischemic tolerance provokes the attenuation of
broad categories of injury-inducing mechanisms, including excito-
toxicity, ion/pH imbalance, oxidative and nitrosative stress, metabolic
Figure 2. Flash VEPs in eyes injected with vehicle or CS without or with ischemia pulses. Animals were weekly injected with vehicle or CS
for 10 weeks. Ischemia pulses were applied in one eye, while the contralateral eye was submitted to a sham procedure. Left panel shows average
amplitudes of VEP N2-P2 component amplitude and right panel shows representative VEP traces. A significant reduction in flash VEP N2-P2 amplitude
component was observed in eyes injected with CS for 10 weeks without ischemia pulses. The application of weekly ischemia pulses significantly
abrogated the effect of ocular hypertension. No changes between vehicle injected eyes without or with ischemia pulses were observed. Data are
mean 6 SEM (n=10 eyes/group), **p,0.01 versus vehicle injected eyes without ischemia pulses (sham), a: p,0.05 versus CS-injected eyes without
ischemia pulses (sham), by Tukey’s test.
doi:10.1371/journal.pone.0023763.g002
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cell death (reviewed in [15]). Several of these mechanisms have been
involved in glaucomatous damage. Thus, although the present
results do not necessarily support the involvement of retinal ischemia
in glaucoma, they indicate that protection against glaucomatous
damage can be achieved by the induction of ischemic tolerance.
Many exogenously delivered chemical preconditioning agents
(for example, inflammatory cytokines, anaesthetics, and metabolic
Figure 3. Retinal histology examination after 10 weeks of ocular hypertension. Upper panel: Representative photomicrographs of retinal
sections stained with hematoxylin and eosin from a vehicle-injected eye, and a hypertensive eye without or with pulses of ischemia. Note the
diminution of GCL cells in the eye injected with CS without ischemia pulses. The application of ischemia pulses preserved this parameter. The other
retinal layers showed a normal appearance in all groups. Middle panel: Immunohistochemical detection of NeuN-positive neurons in the GCL from a
vehicle-injected eye, a hypertensive eye without or with ischemia pulses. A strong NeuN-immunostaining (red) was confined to ganglion cells in the
GCL. The number of NeuN positive ganglion cells was lower in hypertensive eyes without ischemia pulses than in vehicle- injected eyes, whereas the
application of ischemia pulses in CS-injected eyes increased NeuN-immunostaining. A similar profile was observed for cell nuclei counterstained with
DAPI (blue). Lower Panel: cell count in the GCL evaluated by H&E staining, NeuN immunostaining, and DAPI labeling. By all these methods, a
significant decrease of the number of cells in the GCL was observed in CS- injected eyes without ischemia pulses as compared with vehicle-injected
eyes (sham), whereas ischemia pulses significantly preserved this parameter in CS-injected eyes. Scale bar: Upper panel = 50 mm; Middle panel =
50 mm. Data are the mean 6 SEM (n=5 animals per group). * p,0.05, ** p,0.01 vehicle injected eyes without ischemia pulses (sham), a: p,0.05, b:
p,0.01 versus CS-injected eyes without ischemia pulses (sham), by Tukey’s test. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear
layer; OPL, outer plexiform layer; ONL, outer nuclear layer.
doi:10.1371/journal.pone.0023763.g003
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inthefuture,IPCandPostCcouldbepharmacologically‘‘mimicked’’
in vivo [15]. Therefore, the present results support that induction
of ischemic tolerance could constitute a fertile avenue for the
development of new therapeutic strategies in glaucoma treatment.
Materials and Methods
Ethics Statement
All animal procedures were in strict accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. The ethic committee of the School of Medicine,
University of Buenos Aires (Institutional Committee for the Care
and Use of Laboratory Animals, (CICUAL)) approved this study.
Animals
Male Wistar rats (average weight 250640 g) were housed in a
standard animal room with food and water ad libitum under
controlled conditions of humidity and temperature (21u62uC).
The room was lighted by fluorescent lights that were turned on
and off automatically every 12 hours, with the lights (200 lux) on
from 6.00 A.M. to 6.00 P.M. A total number of 84 animals were
used for the experiments, distributed as follows: 10 animals
bilaterally injected with vehicle (control) and 10 animals bilaterally
injected with CS for IOP, ERG and VEP assessment at 10 weeks
of treatment, 5 control and 5 CS-injected animals for histological
studies, 5 animals of each group (control and CS) for the study of
the ONH, and 12 control and 12 CS animals for TBARS
assessment. Moreover, 10 control and 10 CS-injected animals
were used for the IOP assessment at different time points, and 5
retinas per group from these animals were used for TUNEL, and
Thy-1 analysis.
Intracameral injections
Rats were anesthetized with ketamine hydrochloride (150
mg/kg) and xylazine hydrochloride (2 mg/kg) administered
Figure 4. Thy-1 level and TUNEL assessment after 10 weeks of ocular hypertension. Representative photomicrographs showing Thy-1
immunofluorescence (upper panel) and TUNEL analysis (middle panel) from a vehicle-injected eye, and a hypertensive eye without or with pulses of
ischemia. Note TUNEL
+ cells in the GCL (arrows). Cell nuclei were counterstained with DAPI. Lower panel: The number of Thy-1 positive cells was
significantly lower in hypertensive eyes without ischemia pulses than in vehicle- injected eyes, whereas the application of ischemia pulses in CS-
injected eyes increased Thy-1 immunostaining. The number of TUNEL
+ cells in the GCL was significantly higher in hypertensive eyes submitted to a
sham procedure than in those submitted to ischemia pulses. No TUNEL
+ cells were observed in vehicle-injected eyes submitted to ischemia pulses or
sham procedure (not shown). Scale bar: 30 mm. Data are mean 6 SEM (n=5 eyes per group). For TUNEL analysis: * p,0.05 versus CS-injected eyes
submitted to sham procedure, by Students t-test; For Thy-1 analysis: **p,0.01 versus vehicle injected eyes without ischemia pulses (sham), a:
p,0.01, versus CS-injected eyes without ischemia pulses (sham), by Tukey’s test.
doi:10.1371/journal.pone.0023763.g004
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Louis, MO, USA, catalog # C9819, isolated from bovine trachea.
Using a Hamilton syringe with a 30-gauge needle, 20 mlo fC S
(0.4 g/ml in saline solution) were injected in both eyes, whereas
control animals were bilaterally injected with saline solution
(Figure 7). The eyes were focused under a Carl Zeiss (model
OMNI MDU XY, Carl Zeiss, Oberkochen, Germany) surgical
microscope with coaxial light. The needle moved through the
corneoscleral limbus to the anterior chamber with the bevel down.
When the tip of the bevel reached the anterior chamber, the liquid
progressively increased the chamber’s depth, separating the needle
from the iris and avoiding needle-lens contact. Applications were
made slowly but using a force sufficient to just empty the syringe
content (adjusted to 20 ml). In the chronic protocol, injections were
applied at the corneoscleral limbus beginning from hour 12 and
changing the site of the next injection from hour to hour by
rotating the head to achieve better access to the limbus. The
injections and IOP assessments were performed after applying one
dropof0.5%proparacaine hydrochloridetoeach eye.Ratsshowing
cataract (less than 4%) were excluded from the experiments. In
addition, almost all the animals developed a localized corneal
edema at the site of the injection that lasted less than 24 h. No
differences in the incidence of these ocular complications were
detected between CS and saline-injected eyes, and between eyes
submitted to ischemia pulses and those submitted to a sham
procedure.
Figure 5. ONH sections from a control or a CS-treated eye without or with ischemia pulses. (A) Healthy, intact control optic nerve. Note
the homogeneity of the staining. In vehicle-injected eyes, individual axons were generally uniform in shape, rounded and packed together tightly to
form the fibers of the healthy nerve. In CS-treated eye without ischemia pulses (B) a less stained area indicates a nerve alteration. Disease in individual
axons was characterized by axonal distention and distortion that resulted in a departure from the circular morphology of normal axons. In contrast, a
conserved structure of the ONH was observed in the CS-treated eye with ischemia pulses (C). Toluidine blue. (D) Number of axons in eyes injected
with vehicle or CS without or with ischemia pulses. A significant decrease in the axon number was observed in CS- injected eyes without ischemia
pulses as compared with vehicle-injected eyes (sham), whereas ischemia pulses significantly preserved this parameter. Scale bar: 10 mm. Data are
mean 6 SEM (n=5 eyes/group) *p,0.05 vehicle injected eyes without ischemia pulses (sham), a: p,0.05 versus CS-injected eyes without ischemia
pulses (sham), by Tukey’s test.
doi:10.1371/journal.pone.0023763.g005
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Rats were assigned to different groups depicted in Figure 7.
Ischemia pulses were applied in one eye from animals bilaterally
injected with vehicle or CS, whereas the contralateral eye was
cannulated without raising IOP (sham procedure). The selection of
eyes that received ischemia pulses or sham treatment was
performed at random. Before ischemia pulse or sham procedure
application, IOP was assessed in both eyes from each animal, and
the starting IOP values did not differ between both eyes from the
same animal. Animals were anesthetized with ketamine hydro-
chloride (150 mg/kg) and xylazine hydrochloride (2 mg/kg)
administered intraperitoneally. After topical instillation of propar-
acaine, the anterior chamber was cannulated with a 30-gauge
needle connected to a pressurized bottle filled with sterile normal
saline solution. Retinal ischemia was induced by increasing IOP to
120 mm Hg for exactly 5 min, as previously described [18]. With
this maneuver, complete ocular ischemia was produced, charac-
terized by the loss of electroretinogram (ERG) b-waves and the
cessation of flow in retinal vessels, determined by funduscopic
examination. Brief retinal ischemia was weekly applied, starting at
6 weeks of ocular hypertension and continuing until week 10.
During ischemia pulses, animals were kept normothermic with
heated blankets. Each ischemia pulse was applied 4 days after the
injection of vehicle or CS.
IOP assessments
A TonoPen XL (Mentor, Norwell, MA) tonometer was used to
assess IOP in conscious, unsedated rats as previously described [1].
IOP determinations were assessed by operators who were blind
with respect to the treatment applied to each eye. Animals were
wrapped in a small towel and held gently, with one operator
holding the animal and another making the readings. Five IOP
readings were obtained from each eye by using firm contact with
the cornea and omitting readings obtained as the instrument was
removed from the eye. The mean of these readings was recorded
as the IOP for this eye. Mean values from each rat were averaged,
and the resultant mean value was used to compute the groups
mean IOP 6 SE. Differences among reading were less than 10%
(standard error).
Electroretinography
Electroretinographic activity was registered as previously
described [1,18]. Briefly, after 6 h of dark adaptation, rats were
Figure 6. Retinal TBARS levels in animals injected with CS or
vehicle, without o with ischemia pulses. This parameter was
significantly higher in eyes injected with CS without ischemia pulses
than in those injected with vehicle. The application of brief ischemia
pulses in CS-injected significantly reversed the increase in retinal lipid
peroxidation. Data are mean 6 SEM (n=12 eyes/group), * p,0.05,
**p,0.01 vs. vehicle injected eyes without ischemia pulses (sham), a:
p,0.05 vs. CS-injected eyes submitted to a sham procedure, by Tukey’s
test.
doi:10.1371/journal.pone.0023763.g006
Figure 7. Experimental groups. Ischemia pulses or a sham procedure were applied 4 days after a once-a-week intracameral injection of vehicle or
CS, starting after 6 weekly intracameral injections.
doi:10.1371/journal.pone.0023763.g007
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chloride and tropicamide were used to dilate the pupils, and the
cornea was intermittently irrigated with balanced salt solution to
maintain the baseline recording and to prevent keratopathy. Rats
were placed facing the stimulus at a distance of 20 cm. All
recordings were completed within 20 min and animals were kept
warm during and after the procedure. A reference electrode was
placed through the ear, a grounding electrode was attached to the
tail, and a gold electrode was placed in contact with the central
cornea. A 15W red light was used to enable accurate electrode
placement. This maneuver did not significantly affect dark
adaptation and was switched off during the electrophysiological
recordings. ERGs were recorded from both eyes simultaneously
and ten responses to flashes of unattenuated white light (5 ms,
0.2 Hz) from a photic stimulator (light-emitting diodes) set at
maximum brightness (0.95 log cd.s/m
2 without filter) were
amplified, filtered (1.5-Hz low-pass filter, 1000 high-pass filter,
notch activated) and averaged (Akonic BIO-PC, Argentina). The
a-wave was measured as the difference in amplitude between the
recording at onset and the trough of the negative deflection and
the b-wave amplitude was measured from the trough of the a-wave
to the peak of the b-wave. Electrophysiological responses were
averaged for each run. Runs were repeated 3 times with 5 min-
intervals to confirm consistency and the mean of these 3 runs was
used for subsequent analysis. The mean peak latencies and peak-
to-peak amplitudes of the responses from each group of rats were
compared.
Flash visual evoked potentials
Scotopic flash visual evoked potentials (VEPs) were registered as
previously described [1]. For this purpose, two stainless steel
electrodes were surgically placed 4 mm lateral to the interhemi-
spheric fissure and 5,6 mm behind bregma (active electrode).
Reference electrodes were placed 2 mm lateral to the midline and
2 mm before bregma. A ground electrode was placed in the
animal tail. Both electrodes were isolated and fixed with dental
acrylic and the skin was sutured with nylon 5/0. Five days after
electrode implantation, VEPs were assessed as follows: after 6 h of
dark adaptation, rats were anaesthetized, pupils were dilated and
the cornea was intermittently irrigated as previously described,
under dim red illumination. All recordings were completed within
20 min of the induction of anaesthesia and animals were kept
warm during and after the procedure. Each eye was registered
individually, occluding the contralateral eye with black carbon
paper and cotton, and a 70 stimuli average was registered. Eyes
were stimulated with unattenuated white light (1 Hz) from a
photic stimulator (light-emitting diodes) set at maximum bright-
ness (0.95 log cd.s/m
2) were amplified, filtered (0.5-Hz low-pass
filter, 100 high-pass filter, notch activated) and averaged (Akonic
BIO-PC, Akonic, Buenos Aires, Argentina). The amplitude
between the N2 deflection and the P2 peak was assessed, and
the N2 latency was measured from de onset to the second negative
peak.
Light Microscopy
Eyes were enucleated after anesthetic overdose and immersed
immediately in a fixative containing 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.2) for 1 h. The nictitans membrane
was maintained in each eye to facilitate orientation. The cornea
and the lens were carefully removed, and the posterior portions
were fixed for an additional 12 h- period in the same fixative. A
cross section of the optic nerve from vehicle and CS-treated eyes
was removed 1.5 mm posterior to the globe and postfixed in 1%
osmium tetroxide in phosphate buffer. Nerves were processed into
epoxy resin, sectioned at 1 mm, and stained with 1% toluidine blue.
Eyecups were dehydrated in an alcohol series, and embedded in
paraffin. Sections (5 mm thick) were cut along the horizontal
meridianthroughtheONHandstainedwithhematoxylinandeosin
(H&E) or used for immunofluorescence and TUNEL analysis.
NeuN and Thy-1 immunofluorescence
Antigen retrieval was performed by heating (90uC) slices for
30 min in citrate buffer and then preincubated with 2% normal
horse serum, 0.1% bovine serum albumin, and 0.4% Triton X-
100 in 0.01 M phosphate-buffered saline for 1 h. The sections
were then incubated overnight at 4uC with a mouse monoclonal
anti-NeuN antibody (1:120; Millipore) or anti-Thy-1 antibody
(1:1000 Millipore). An anti-mouse secondary antibody conjugated
to Alexa Fluor 568 (1:500; Molecular Probes) was used. After
immunostaining, the sections were mounted with antifade medium
with the fluorescent dye DAPI (Vector Laboratories). Some
sections were treated without the primary antibodies to confirm
specificity. An Olympus BX50 microscope (Olympus, Tokyo,
Japan) was used for microscopic observations. Comparative digital
images from different samples were grabbed using identical time
exposition, brightness, and contrast settings.
Image analysis
Microscopic images were digitally captured with a Nikon
Eclipse E400 microscope (illumination: 6-V halogen lamp, 20W,
equipped with a stabilized light source) attached to a digital
camera (Coolpix s10; Nikon). The digitalized images were
transferred to a Scion Image for Windows analysis system (Scion
Corporation Beta 4.0.2).
Retinal morphometry was evaluated as described by Takahata
et al., (2003) [35], with minor modifications. Three sections were
randomly selected from each eye. Nine microscopic images at
1 mm from the temporal edge of the optic disc were digitally
analyzed. The light microscope was adjusted to level 4 and a 40x
CF E achromat objective was used. The thickness (in mm) of the
inner plexiform layer (IPL), inner nuclear layer (INL), outer
plexiform layer (OPL), outer nuclear layer (ONL), and total retina
was measured. The number of cells in the ganglion cell layer
(GCL) was expressed as cells per 100 mm. For each eye, results
obtained from three separate sections were averaged and the mean
of 5 eyes was recorded as the representative value for each group.
No attempt was made to distinguish cell types in the GCL for
enumeration of cell number. The morphometric analysis was
performed by observers masked to the protocol used in each eye.
TUNEL analysis
For DNA fragmentation of cells undergoing apoptosis, the
ApopTagH Fluorecein In Situ Apoptosis Detection Kit (S7110,
Chemicon, CA, USA) was used according to manufacturer’s
instructions. For each retinal section, the number of TUNEL
+ cells
along the entire retina was calculated. For each eye, results obtained
from four separate sections were averaged and the mean of five eyes
was recorded as the representative value for each group.
Optic nerve morphometry
Optic nerve axon counting was performed as previously de-
scribed [1]. To measure axon density, images were captured with a
100X achromat objective from 5 spaced nerve regions. Images were
converted to 8-bits grey scale and a manual threshold value, first
determined by visual examination, was constantly applied. Finally,
images were converted to a binary form. The number of axons
counted in 5 images from each nerve was approximately 10% of the
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observers masked to the protocol used in each nerve.
Measurement of TBARS levels
TBARS levels in retinal tissue were analyzed as previously
described [11]. Retinas were homogenized in 15 mM potassium
buffer plus 60 mM KCl, pH 7.2. The homogenate (300 ml) was
mixed with 75 ml 10% SDS and 1.4 ml of 0.8% thiobarbituric acid
dissolved in 10% acetic acid (pH 3.5). This solution was heated to
100uC for 60 min. After cooling, the flocculent precipitate was
removed by centrifugation at 3200 x g for 10 min. After addition
of 1.0 ml water and 5.0 ml of n-butanol-pyridine mixture (15:1,
vol/vol), the mixture was vigorously shaken and centrifuged at
2000 x g for 15 min. The absorbance of the organic layer was
measured at an emission wavelength of 553 nm by using an
excitation wavelength of 515 nm with a Jasco FP 770 fluorescence
spectrophotometer (Japan Spectroscopic Co. Ltd. Tokyo, Japan).
The range of the standard curves of malondialdehyde bis-dimethyl
acetal (MDA) was 10–2000 pmol. Results were expressed as
nanomol MDA per mg of protein.
Protein content was determined by the method of Lowry et al.,
(1951) [36], using bovine serum albumin as the standard.
Statistical analysis
Statistical analysis of results was made by a Student’s t-test or by
a two-way analysis of variance (ANOVA) followed by Student’s t-
test or Dunnett’s test, as stated.
Author Contributions
Conceived and designed the experiments: NB PHS NdZ DCF DMS MSC
RER. Performed the experiments: NB PHS NdZ DCF DMS MSC.
Analyzed the data: NB RER. Wrote the paper: NB RER.
References
1. Belforte N, Sande P, de Zavalı ´a N, Knepper PA, Rosenstein RE (2010) Effect of
chondroitin sulfate on intraocular pressure in rats. Invest Ophthalmol Vis Sci 51:
5768–5775.
2. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, et al. (1999)
Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv
Ophthalmol 43: S43–50.
3. Flammer J (1994) The vascular concept of glaucoma. Surv Ophthalmol 38:
S3–6.
4. Delaney Y, Walshe TE, O’Brien C (2006) Vasospasm in glaucoma: clinical and
laboratory aspects. Optom Vis Sci 83: 406–414.
5. Gugleta K (2009) Vascular risk factors in glaucoma – diagnostics. Praxis (Bern
1994) 98: 201–207.
6. Flammer J, Orgu ¨l S, Costa VP, Orzalesi N, Krieglstein GK, et al. (2002) The
impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21: 359–393.
7. Fuchsja ¨ger-Mayrl G, Wally B, Georgopoulos M, Rainer G, Kircher K, et al.
(2004) Ocular blood flow and systemic blood pressure in patients with primary
open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 45:
834–839.
8. Galassi F, Sodi A, Ucci F, Renieri G, Pieri B, et al. (2003) Ocular hemodynamics
and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol 121:
1711–1715.
9. Zink JM, Grunwald JE, Piltz-Seymour J, Staii A, Dupont J (2003) Association
between lower optic nerve laser Doppler blood volume measurements and
glaucomatous visual field progression. Br J Ophthalmol 87: 1487–1491.
10. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, et al. (2004)
Retinal ischemia: mechanisms of damage and potential therapeutic strategies.
Prog Retin Eye Res 23: 91–147.
11. Moreno MC, Campanelli J, Sande P, Sa ´nez DA, Keller Sarmiento MI, et al.
(2004) Retinal oxidative stress induced by high intraocular pressure. Free Radic
Biol Med 37: 803–812.
12. Moreno MC, Sande P, Marcos HA, de Zavalı ´a N, Keller Sarmiento MI, et al.
(2005) Effect of glaucoma on the retinal glutamate/glutamine cycle activity.
FASEB J 19: 1161–1162.
13. Roth S, Li B, Rosenbaum PS, Gupta H, Goldstein IM, et al. (1998)
Preconditioning provides complete protection against retinal ischemic injury in
rats. Invest Ophthalmol Vis Sci 39: 777–785.
14. Roth S (2004) Endogenous neuroprotection in the retina. Brain Res Bull 62:
461–466.
15. Gidday JM (2006) Cerebral preconditioning and ischaemic tolerance. Nat Rev
Neurosci 7: 437–448.
16. Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, et al. (1996) Ventricular
premature beat-driven intermittent restoration of coronary blood flow reduces
the incidence of reperfusion-induced ventricular fibrillation in a cat model of
regional ischemia. Am Heart J 132: 78–83.
17. Zhao H, Sapolsky RM, Steinberg GK (2006) Interrupting reperfusion as a stroke
therapy: ischemic postconditioning reduces infarct size after focal ischemia in
rats. J Cereb Blood Flow Metab 26: 1114–1121.
18. Fernandez DC, Bordone MP, Chianelli MS, Rosenstein RE (2009) Retinal
neuroprotection against ischemia-reperfusion damage induced by postcondition-
ing. Invest Ophthalmol Vis Sci 50: 3922–3930.
19. Chauhan BC, Pan J, Archibald ML, LeVatte TL, Kelly ME, et al. (2002) Effect
of intraocular pressure on optic disc topography, electroretinography, and
axonal loss in a chronic pressure-induced rat model of optic nerve damage.
Invest Ophthalmol Vis Sci 43: 2969–2976.
20. Viswanathan S, Frishman LJ, Robson JG (2000) The uniform field and pattern
ERG in macaques with experimental glaucoma: removal of spiking activity.
Invest Ophthalmol Vis Sci 41: 2797–2810.
21. Grippo TM, Hood DC, Kanadani FN, Ezon I, Greenstein VC, et al. (2006) A
comparison between multifocal and conventional VEP latency changes
secondary to glaucomatous damage. Invest Ophthalmol Vis Sci 47: 5331–5336.
22. Papst N, Bopp M, Schnaudigel OE (1984) Pattern electroretinogram and
visually evoked cortical potentials in glaucoma. Graefes Arch Clin Exp
Ophthalmol 222: 29–33.
23. Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, et al. (2008)
Progressive ganglion cell degeneration precedes neuronal loss in a mouse model
of glaucoma. J Neurosci 28: 2735–2744.
24. Canola K, Ange ´nieux B, Tekaya M, Quiambao A, Naash MI, et al. (2007)
Retinal stem cells transplanted into models of late stages of retinitis pigmentosa
preferentially adopt a glial or a retinal ganglion cell fate. Invest Ophthalmol Vis
Sci 48: 446–454.
25. Dijk F, Bergen AA, Kamphuis W (2007) GAP-43 expression is upregulated in
retinal ganglion cells after ischemia/reperfusion-induced damage. Exp Eye Res
84: 858–867.
26. Yamamoto T, Kitazawa Y (1998) Vascular pathogenesis of normal-tension
glaucoma: a possible pathogenetic factor, other than intraocular pressure, of
glaucomatous optic neuropathy. Prog Retin Eye Res 17: 127–143.
27. Quigley HA (1999) Neuronal death in glaucoma. Prog Retin Eye Res 18: 39–57.
28. Tezel G (2006) Oxidative stress in glaucomatous neurodegeneration: mecha-
nisms and consequences. Prog Retin Eye Res 25: 490–513.
29. Li B, Yang C, Rosenbaum DM, Roth S (2000) Signal transduction mechanisms
involved in ischemic preconditioning in the rat retina in vivo. Exp Eye Res 70:
755–765.
30. Sakamoto K, Kuwagata M, Nakahara T, Ishii K (2001) Late preconditioning in
rat retina: involvement of adenosine and ATP-sensitive K(+)c h a n n e l .
Eur J Pharmacol 418: 89–93.
31. Yu SY, Chiu JH, Yang SD, Yu HY, Hsieh CC, et al. (2005) Preconditioned
hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in
rats. J Surg Res 128: 28–36.
32. Kwong JM, Lam TT, Caprioli J (2003) Hyperthermic pre-conditioning protects
retinal neurons from N-methyl-D-aspartate (NMDA)-induced apoptosis in rat.
Brain Res 970: 119–130.
33. Franco PJ, Fernandez DC, Sande PH, Keller Sarmiento MI, Chianelli M, et al.
(2008) Effect of bacterial lipopolysaccharide on ischemic damage in the rat
retina. Invest Ophthalmol Vis Sci 49: 4604–4612.
34. Casson RJ, Wood JP, Melena J, Chidlow G, Osborne NN (2003) The effect of
ischemic preconditioning on light-induced photoreceptor injury. Invest
Ophthalmol Vis Sci 44: 1348–1354.
35. Takahata K, Katsuki H, Kume T, Nakata D, Ito K, et al. (2003) Retinal
neuronal death induced by intraocular administration of a nitric oxide donor
and its rescue by neurotrophic factors in rats. Invest Ophthalmol Vis Sci 44:
1760–1766.
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement
with the Folin phenol reagent. J Biol Chem 193: 265–275.
Ischemic Tolerance and Glaucoma
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23763